Rasburicase
Mechanism :
Rasburicase is a recombinant urate-oxidase enzyme, which converts uric acid to allantoin.
Indication :
- Hyperuricemia associated with malignancy
Contraindications :
History of anaphylaxis or severe hypersensitivity to rasburicase or any component of the formulation; history of hemolytic reaction or methemoglobinemia associated with rasburicase; glucose-6-phosphatase dehydrogenase (G6PD) deficiency.
Dosing :
IV:
0.2 mg/kg once daily for up to 5 days.
Adverse Effect :
Peripheral edema, headache, anxiety, rash, hypophosphatemia, hypervolemia, nausea, vomiting, abdominal pain, hyperbilirubinemia, increased serum ALT, antibody development, sepsis, fever.
Interaction :
No known significant interactions.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
| 20-50 | Dose as in normal renal function |
| 10-20 | Dose as in normal renal function |
| <10 | Dose as in normal renal function |
Dose in Patients undergoing Renal Replacement Therapies
| CAPD | Unlikely to be dialysed. Dose as in normal renal function |
| HD | Unlikely to be dialysed. Dose as in normal renal function |
| HDF/High flux | Unlikely to be dialysed. Dose as in normal renal function |
| CAV/VVHD | Unlikely to be dialysed. Dose as in normal renal function |
Hepatic Dose :
No dose adjustment recommended.